Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial Article Swipe
Raphaël Steiner
,
Liana Nikolaenko
,
Ranjit Nair
,
Venkatraman Seshan
,
Swetha Kambhampati
,
Niloufer Khan
,
Jeremy S. Abramson
,
Steven M. Horwitz
,
Matthew J. Matasar
,
Colette Owens
,
Ildefonso Rodriguez-Rivera
,
David Strauss
,
Timothy S. Pardee
,
Sanjeev Luther
,
Sabrina Saboukoulou
,
Win Su Thet
,
Shreya Vemuri
,
Ariela Noy
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1182/bloodadvances.2025016168
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1182/bloodadvances.2025016168
Patients with primary refractory or relapsed (R/R) MYC-driven aggressive B-cell lymphomas, such as Burkitt lymphoma (BL), plasmablastic lymphoma (PBL), and double-hit lymphoma (DHL)/triple-hit lymphoma (THL), have a dismal prognosis with few survivors. The deregulated MYC protein drives proliferation with dependence on tricarboxylic acid cycle intermediates as biosynthetic precursors. Devimistat disrupts mitochondrial production of adenosine triphosphate and biosynthetic intermediates. We conducted a phase 2 trial to explore the efficacy of devimistat in R/R-BL, R/R-PBL, and R/R-DHL, administered daily for 5 days every 14 days for 2 cycles, followed by maintenance for 5 days every 21 days until progression, toxicity, or transplant. No responses were seen in the 2 enrolled patients with R/R-PBL and 9 with R/R-DHL/THL. Among the 13 patients with R/R-BL, 2 had a complete response (CR), resulting in a CR rate (CRR) of 15%, whereas the others experienced rapid disease progression. The median follow-up time for patients with R/R-BL was 1 month (range, 0-47). Among the 2 patients with R/R-BL CR, the response duration was 8 months in 1 and ongoing at the time of data cutoff, 17 months after study entry. Overall, 3 patients had grade 3 events at least possibly related to the study drug: neutropenia, thrombocytopenia, headache, noncardiac chest pain, and increase of troponin. Considering the dismal prognosis of R/R MYC-driven aggressive B-cell lymphomas with the current standard of care and low CRR with devimistat, efforts should be made to improve the outcome of these malignancies with their first line of therapy and explore novel therapies in the R/R setting. This trial was registered at www.ClinicalTrials.gov as #NCT03793140.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1182/bloodadvances.2025016168
- OA Status
- gold
- References
- 22
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4412491337
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4412491337Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1182/bloodadvances.2025016168Digital Object Identifier
- Title
-
Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trialWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-07-17Full publication date if available
- Authors
-
Raphaël Steiner, Liana Nikolaenko, Ranjit Nair, Venkatraman Seshan, Swetha Kambhampati, Niloufer Khan, Jeremy S. Abramson, Steven M. Horwitz, Matthew J. Matasar, Colette Owens, Ildefonso Rodriguez-Rivera, David Strauss, Timothy S. Pardee, Sanjeev Luther, Sabrina Saboukoulou, Win Su Thet, Shreya Vemuri, Ariela NoyList of authors in order
- Landing page
-
https://doi.org/10.1182/bloodadvances.2025016168Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1182/bloodadvances.2025016168Direct OA link when available
- Concepts
-
Medicine, Neutropenia, Lymphoma, Internal medicine, Gastroenterology, Burkitt's lymphoma, Refractory (planetary science), Toxicity, Biology, AstrobiologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
22Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4412491337 |
|---|---|
| doi | https://doi.org/10.1182/bloodadvances.2025016168 |
| ids.doi | https://doi.org/10.1182/bloodadvances.2025016168 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40674734 |
| ids.openalex | https://openalex.org/W4412491337 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000188 |
| mesh[1].descriptor_ui | D002051 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | drug therapy |
| mesh[1].descriptor_name | Burkitt Lymphoma |
| mesh[2].qualifier_ui | Q000401 |
| mesh[2].descriptor_ui | D002051 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | mortality |
| mesh[2].descriptor_name | Burkitt Lymphoma |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D005260 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Female |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D008297 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Male |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D008875 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Middle Aged |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D000328 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Adult |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D000368 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Aged |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D012074 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Remission Induction |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D016896 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Treatment Outcome |
| mesh[10].qualifier_ui | Q000627 |
| mesh[10].descriptor_ui | D000970 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | therapeutic use |
| mesh[10].descriptor_name | Antineoplastic Agents |
| mesh[11].qualifier_ui | Q000009 |
| mesh[11].descriptor_ui | D000970 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | adverse effects |
| mesh[11].descriptor_name | Antineoplastic Agents |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D006801 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Humans |
| mesh[13].qualifier_ui | Q000188 |
| mesh[13].descriptor_ui | D002051 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | drug therapy |
| mesh[13].descriptor_name | Burkitt Lymphoma |
| mesh[14].qualifier_ui | Q000401 |
| mesh[14].descriptor_ui | D002051 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | mortality |
| mesh[14].descriptor_name | Burkitt Lymphoma |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D005260 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Female |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D008297 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Male |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D008875 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Middle Aged |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D000328 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Adult |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D000368 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Aged |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D012074 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Remission Induction |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D016896 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Treatment Outcome |
| mesh[22].qualifier_ui | Q000627 |
| mesh[22].descriptor_ui | D000970 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | therapeutic use |
| mesh[22].descriptor_name | Antineoplastic Agents |
| mesh[23].qualifier_ui | Q000009 |
| mesh[23].descriptor_ui | D000970 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | adverse effects |
| mesh[23].descriptor_name | Antineoplastic Agents |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D006801 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Humans |
| mesh[25].qualifier_ui | Q000188 |
| mesh[25].descriptor_ui | D002051 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | drug therapy |
| mesh[25].descriptor_name | Burkitt Lymphoma |
| mesh[26].qualifier_ui | Q000401 |
| mesh[26].descriptor_ui | D002051 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | mortality |
| mesh[26].descriptor_name | Burkitt Lymphoma |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D005260 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Female |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D008297 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Male |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D008875 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Middle Aged |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D000328 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Adult |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D000368 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Aged |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D012074 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Remission Induction |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D016896 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Treatment Outcome |
| mesh[34].qualifier_ui | Q000627 |
| mesh[34].descriptor_ui | D000970 |
| mesh[34].is_major_topic | True |
| mesh[34].qualifier_name | therapeutic use |
| mesh[34].descriptor_name | Antineoplastic Agents |
| mesh[35].qualifier_ui | Q000009 |
| mesh[35].descriptor_ui | D000970 |
| mesh[35].is_major_topic | True |
| mesh[35].qualifier_name | adverse effects |
| mesh[35].descriptor_name | Antineoplastic Agents |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D006801 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Humans |
| mesh[37].qualifier_ui | Q000188 |
| mesh[37].descriptor_ui | D002051 |
| mesh[37].is_major_topic | True |
| mesh[37].qualifier_name | drug therapy |
| mesh[37].descriptor_name | Burkitt Lymphoma |
| mesh[38].qualifier_ui | Q000401 |
| mesh[38].descriptor_ui | D002051 |
| mesh[38].is_major_topic | True |
| mesh[38].qualifier_name | mortality |
| mesh[38].descriptor_name | Burkitt Lymphoma |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D005260 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Female |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D008297 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Male |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D008875 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | Middle Aged |
| mesh[42].qualifier_ui | |
| mesh[42].descriptor_ui | D000328 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | |
| mesh[42].descriptor_name | Adult |
| mesh[43].qualifier_ui | |
| mesh[43].descriptor_ui | D000368 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | |
| mesh[43].descriptor_name | Aged |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D012074 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Remission Induction |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D016896 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Treatment Outcome |
| mesh[46].qualifier_ui | Q000627 |
| mesh[46].descriptor_ui | D000970 |
| mesh[46].is_major_topic | True |
| mesh[46].qualifier_name | therapeutic use |
| mesh[46].descriptor_name | Antineoplastic Agents |
| mesh[47].qualifier_ui | Q000009 |
| mesh[47].descriptor_ui | D000970 |
| mesh[47].is_major_topic | True |
| mesh[47].qualifier_name | adverse effects |
| mesh[47].descriptor_name | Antineoplastic Agents |
| type | article |
| title | Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial |
| biblio.issue | 21 |
| biblio.volume | 9 |
| biblio.last_page | 5563 |
| biblio.first_page | 5556 |
| topics[0].id | https://openalex.org/T10185 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9990000128746033 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2734 |
| topics[0].subfield.display_name | Pathology and Forensic Medicine |
| topics[0].display_name | Lymphoma Diagnosis and Treatment |
| topics[1].id | https://openalex.org/T12534 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9886999726295471 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Protein Degradation and Inhibitors |
| topics[2].id | https://openalex.org/T10631 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.972000002861023 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1306 |
| topics[2].subfield.display_name | Cancer Research |
| topics[2].display_name | Cancer, Hypoxia, and Metabolism |
| is_xpac | False |
| apc_list.value | 3000 |
| apc_list.currency | USD |
| apc_list.value_usd | 3000 |
| apc_paid.value | 3000 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 3000 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.660912275314331 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2777063308 |
| concepts[1].level | 3 |
| concepts[1].score | 0.6321779489517212 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1435822 |
| concepts[1].display_name | Neutropenia |
| concepts[2].id | https://openalex.org/C2779338263 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6228109002113342 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q208414 |
| concepts[2].display_name | Lymphoma |
| concepts[3].id | https://openalex.org/C126322002 |
| concepts[3].level | 1 |
| concepts[3].score | 0.5967478156089783 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[3].display_name | Internal medicine |
| concepts[4].id | https://openalex.org/C90924648 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5339946150779724 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[4].display_name | Gastroenterology |
| concepts[5].id | https://openalex.org/C2778913318 |
| concepts[5].level | 3 |
| concepts[5].score | 0.44541409611701965 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q1016605 |
| concepts[5].display_name | Burkitt's lymphoma |
| concepts[6].id | https://openalex.org/C142424586 |
| concepts[6].level | 2 |
| concepts[6].score | 0.42611658573150635 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q7307572 |
| concepts[6].display_name | Refractory (planetary science) |
| concepts[7].id | https://openalex.org/C29730261 |
| concepts[7].level | 2 |
| concepts[7].score | 0.3956202268600464 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q274160 |
| concepts[7].display_name | Toxicity |
| concepts[8].id | https://openalex.org/C86803240 |
| concepts[8].level | 0 |
| concepts[8].score | 0.13933539390563965 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[8].display_name | Biology |
| concepts[9].id | https://openalex.org/C87355193 |
| concepts[9].level | 1 |
| concepts[9].score | 0.0 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q411 |
| concepts[9].display_name | Astrobiology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.660912275314331 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/neutropenia |
| keywords[1].score | 0.6321779489517212 |
| keywords[1].display_name | Neutropenia |
| keywords[2].id | https://openalex.org/keywords/lymphoma |
| keywords[2].score | 0.6228109002113342 |
| keywords[2].display_name | Lymphoma |
| keywords[3].id | https://openalex.org/keywords/internal-medicine |
| keywords[3].score | 0.5967478156089783 |
| keywords[3].display_name | Internal medicine |
| keywords[4].id | https://openalex.org/keywords/gastroenterology |
| keywords[4].score | 0.5339946150779724 |
| keywords[4].display_name | Gastroenterology |
| keywords[5].id | https://openalex.org/keywords/burkitts-lymphoma |
| keywords[5].score | 0.44541409611701965 |
| keywords[5].display_name | Burkitt's lymphoma |
| keywords[6].id | https://openalex.org/keywords/refractory |
| keywords[6].score | 0.42611658573150635 |
| keywords[6].display_name | Refractory (planetary science) |
| keywords[7].id | https://openalex.org/keywords/toxicity |
| keywords[7].score | 0.3956202268600464 |
| keywords[7].display_name | Toxicity |
| keywords[8].id | https://openalex.org/keywords/biology |
| keywords[8].score | 0.13933539390563965 |
| keywords[8].display_name | Biology |
| language | en |
| locations[0].id | doi:10.1182/bloodadvances.2025016168 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2764683450 |
| locations[0].source.issn | 2473-9529, 2473-9537 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2473-9529 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Blood Advances |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Blood Advances |
| locations[0].landing_page_url | https://doi.org/10.1182/bloodadvances.2025016168 |
| locations[1].id | pmid:40674734 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Blood advances |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40674734 |
| locations[2].id | pmh:oai:europepmc.org:11423554 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400806 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Europe PMC (PubMed Central) |
| locations[2].source.host_organization | https://openalex.org/I1303153112 |
| locations[2].source.host_organization_name | European Bioinformatics Institute |
| locations[2].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12615278 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5010407419 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-3717-3629 |
| authorships[0].author.display_name | Raphaël Steiner |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I1334819555 |
| authorships[0].affiliations[0].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, New York, New York, United States |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I1334819555 |
| authorships[0].affiliations[1].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, New York, New York, United States. |
| authorships[0].institutions[0].id | https://openalex.org/I1334819555 |
| authorships[0].institutions[0].ror | https://ror.org/02yrq0923 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I1334819555 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Memorial Sloan Kettering Cancer Center |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Raphael E. Steiner |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States. |
| authorships[1].author.id | https://openalex.org/A5001438849 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-0542-1712 |
| authorships[1].author.display_name | Liana Nikolaenko |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1301076528 |
| authorships[1].affiliations[0].raw_affiliation_string | City of Hope Medical Center, Duarte, California, United States |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I1301076528 |
| authorships[1].affiliations[1].raw_affiliation_string | City of Hope Medical Center, Duarte, California, United States. |
| authorships[1].institutions[0].id | https://openalex.org/I1301076528 |
| authorships[1].institutions[0].ror | https://ror.org/00w6g5w60 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1301076528 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | City Of Hope National Medical Center |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Liana Nikolaenko |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | City of Hope Medical Center, Duarte, California, United States, City of Hope Medical Center, Duarte, California, United States. |
| authorships[2].author.id | https://openalex.org/A5111552833 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Ranjit Nair |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I1343551460 |
| authorships[2].affiliations[0].raw_affiliation_string | MD Anderson Cancer Center:, Houston, Texas, United States |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I1343551460 |
| authorships[2].affiliations[1].raw_affiliation_string | MD Anderson Cancer Center:, Houston, Texas, United States. |
| authorships[2].institutions[0].id | https://openalex.org/I1343551460 |
| authorships[2].institutions[0].ror | https://ror.org/04twxam07 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I1343551460 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | The University of Texas MD Anderson Cancer Center |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Ranjit Nair |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | MD Anderson Cancer Center:, Houston, Texas, United States, MD Anderson Cancer Center:, Houston, Texas, United States. |
| authorships[3].author.id | https://openalex.org/A5041344703 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-9258-2698 |
| authorships[3].author.display_name | Venkatraman Seshan |
| authorships[3].affiliations[0].raw_affiliation_string | MSKCC, New York, New York, United States |
| authorships[3].affiliations[1].raw_affiliation_string | MSKCC, New York, New York, United States. |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Venkatraman E Seshan |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | MSKCC, New York, New York, United States, MSKCC, New York, New York, United States. |
| authorships[4].author.id | https://openalex.org/A5102781763 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-5776-3274 |
| authorships[4].author.display_name | Swetha Kambhampati |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I1301076528 |
| authorships[4].affiliations[0].raw_affiliation_string | City of Hope National Medical Center, Duarte, California, United States |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I1301076528 |
| authorships[4].affiliations[1].raw_affiliation_string | City of Hope National Medical Center, Duarte, California, United States. |
| authorships[4].institutions[0].id | https://openalex.org/I1301076528 |
| authorships[4].institutions[0].ror | https://ror.org/00w6g5w60 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I1301076528 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | City Of Hope National Medical Center |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Swetha Thiruvengadam |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | City of Hope National Medical Center, Duarte, California, United States, City of Hope National Medical Center, Duarte, California, United States. |
| authorships[5].author.id | https://openalex.org/A5085214985 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-8631-5710 |
| authorships[5].author.display_name | Niloufer Khan |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I1301076528, https://openalex.org/I4210110459 |
| authorships[5].affiliations[0].raw_affiliation_string | City of Hope, Duarte, California, United States |
| authorships[5].affiliations[1].institution_ids | https://openalex.org/I4210110459 |
| authorships[5].affiliations[1].raw_affiliation_string | City of Hope, Duarte, California, United States. |
| authorships[5].institutions[0].id | https://openalex.org/I1301076528 |
| authorships[5].institutions[0].ror | https://ror.org/00w6g5w60 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I1301076528 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | City Of Hope National Medical Center |
| authorships[5].institutions[1].id | https://openalex.org/I4210110459 |
| authorships[5].institutions[1].ror | https://ror.org/01z1vct10 |
| authorships[5].institutions[1].type | healthcare |
| authorships[5].institutions[1].lineage | https://openalex.org/I1301076528, https://openalex.org/I4210110459 |
| authorships[5].institutions[1].country_code | US |
| authorships[5].institutions[1].display_name | City of Hope |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Niloufer Khan |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States. |
| authorships[6].author.id | https://openalex.org/A5002103749 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-8467-9257 |
| authorships[6].author.display_name | Jeremy S. Abramson |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[6].affiliations[0].raw_affiliation_string | Mass General Cancer Center, Boston, Massachusetts, United States |
| authorships[6].affiliations[1].institution_ids | https://openalex.org/I4210087915 |
| authorships[6].affiliations[1].raw_affiliation_string | Mass General Cancer Center, Boston, Massachusetts, United States. |
| authorships[6].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[6].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Massachusetts General Hospital |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Jeremy S. Abramson |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Mass General Cancer Center, Boston, Massachusetts, United States, Mass General Cancer Center, Boston, Massachusetts, United States. |
| authorships[7].author.id | https://openalex.org/A5069406522 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-6399-2006 |
| authorships[7].author.display_name | Steven M. Horwitz |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I1334819555 |
| authorships[7].affiliations[0].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, New York, New York, United States |
| authorships[7].affiliations[1].institution_ids | https://openalex.org/I1334819555 |
| authorships[7].affiliations[1].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, New York, New York, United States. |
| authorships[7].institutions[0].id | https://openalex.org/I1334819555 |
| authorships[7].institutions[0].ror | https://ror.org/02yrq0923 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I1334819555 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Memorial Sloan Kettering Cancer Center |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Steven M Horwitz |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States. |
| authorships[8].author.id | https://openalex.org/A5049461398 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-4581-3721 |
| authorships[8].author.display_name | Matthew J. Matasar |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I1334819555 |
| authorships[8].affiliations[0].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, United States |
| authorships[8].affiliations[1].institution_ids | https://openalex.org/I1334819555 |
| authorships[8].affiliations[1].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, United States. |
| authorships[8].institutions[0].id | https://openalex.org/I1334819555 |
| authorships[8].institutions[0].ror | https://ror.org/02yrq0923 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I1334819555 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Memorial Sloan Kettering Cancer Center |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Matthew J. Matasar |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Memorial Sloan Kettering Cancer Center, United States, Memorial Sloan Kettering Cancer Center, United States. |
| authorships[9].author.id | https://openalex.org/A5055986807 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Colette Owens |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I1334819555 |
| authorships[9].affiliations[0].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, Middletown, New Jersey, United States |
| authorships[9].affiliations[1].institution_ids | https://openalex.org/I1334819555 |
| authorships[9].affiliations[1].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, Middletown, New Jersey, United States. |
| authorships[9].institutions[0].id | https://openalex.org/I1334819555 |
| authorships[9].institutions[0].ror | https://ror.org/02yrq0923 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I1334819555 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Memorial Sloan Kettering Cancer Center |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Colette N Owens |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Memorial Sloan Kettering Cancer Center, Middletown, New Jersey, United States, Memorial Sloan Kettering Cancer Center, Middletown, New Jersey, United States. |
| authorships[10].author.id | https://openalex.org/A5091619007 |
| authorships[10].author.orcid | https://orcid.org/0000-0001-9211-1768 |
| authorships[10].author.display_name | Ildefonso Rodriguez-Rivera |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I2800124591 |
| authorships[10].affiliations[0].raw_affiliation_string | Texas Oncology & New Experimental Therapeutics, United States |
| authorships[10].affiliations[1].institution_ids | https://openalex.org/I2800124591 |
| authorships[10].affiliations[1].raw_affiliation_string | Texas Oncology & New Experimental Therapeutics, United States. |
| authorships[10].institutions[0].id | https://openalex.org/I2800124591 |
| authorships[10].institutions[0].ror | https://ror.org/02ketev28 |
| authorships[10].institutions[0].type | facility |
| authorships[10].institutions[0].lineage | https://openalex.org/I2800124591 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Texas Oncology |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Ildefonso Ismael Rodriguez-Rivera |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Texas Oncology & New Experimental Therapeutics, United States, Texas Oncology & New Experimental Therapeutics, United States. |
| authorships[11].author.id | https://openalex.org/A5026061248 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-2804-967X |
| authorships[11].author.display_name | David Strauss |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I205783295 |
| authorships[11].affiliations[0].raw_affiliation_string | Weil Cornell, United States |
| authorships[11].affiliations[1].institution_ids | https://openalex.org/I205783295 |
| authorships[11].affiliations[1].raw_affiliation_string | Weil Cornell, United States. |
| authorships[11].institutions[0].id | https://openalex.org/I205783295 |
| authorships[11].institutions[0].ror | https://ror.org/05bnh6r87 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I205783295 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Cornell University |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | David Strauss |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Weil Cornell, United States, Weil Cornell, United States. |
| authorships[12].author.id | https://openalex.org/A5049848146 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-1186-6948 |
| authorships[12].author.display_name | Timothy S. Pardee |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I1282516798 |
| authorships[12].affiliations[0].raw_affiliation_string | Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States |
| authorships[12].affiliations[1].institution_ids | https://openalex.org/I1282516798 |
| authorships[12].affiliations[1].raw_affiliation_string | Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States. |
| authorships[12].institutions[0].id | https://openalex.org/I1282516798 |
| authorships[12].institutions[0].ror | https://ror.org/04v8djg66 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I1282516798, https://openalex.org/I47251452 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | Atrium Health Wake Forest Baptist |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Timothy S. Pardee |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States, Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States. |
| authorships[13].author.id | https://openalex.org/A5004268517 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | Sanjeev Luther |
| authorships[13].affiliations[0].raw_affiliation_string | Ernexa Therapeutics, Hockessin, Delaware, United States |
| authorships[13].affiliations[1].raw_affiliation_string | Ernexa Therapeutics, Hockessin, Delaware, United States. |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Sanjeev Luther |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Ernexa Therapeutics, Hockessin, Delaware, United States, Ernexa Therapeutics, Hockessin, Delaware, United States. |
| authorships[14].author.id | https://openalex.org/A5118154458 |
| authorships[14].author.orcid | |
| authorships[14].author.display_name | Sabrina Saboukoulou |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I1334819555 |
| authorships[14].affiliations[0].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, New York, New York, United States |
| authorships[14].affiliations[1].institution_ids | https://openalex.org/I1334819555 |
| authorships[14].affiliations[1].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, New York, New York, United States. |
| authorships[14].institutions[0].id | https://openalex.org/I1334819555 |
| authorships[14].institutions[0].ror | https://ror.org/02yrq0923 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I1334819555 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Memorial Sloan Kettering Cancer Center |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Sabrina Saboukoulou |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States. |
| authorships[15].author.id | https://openalex.org/A5115010825 |
| authorships[15].author.orcid | |
| authorships[15].author.display_name | Win Su Thet |
| authorships[15].countries | US |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I1334819555 |
| authorships[15].affiliations[0].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, New York, New York, United States |
| authorships[15].affiliations[1].institution_ids | https://openalex.org/I1334819555 |
| authorships[15].affiliations[1].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, New York, New York, United States. |
| authorships[15].institutions[0].id | https://openalex.org/I1334819555 |
| authorships[15].institutions[0].ror | https://ror.org/02yrq0923 |
| authorships[15].institutions[0].type | healthcare |
| authorships[15].institutions[0].lineage | https://openalex.org/I1334819555 |
| authorships[15].institutions[0].country_code | US |
| authorships[15].institutions[0].display_name | Memorial Sloan Kettering Cancer Center |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Win Su Thet |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States. |
| authorships[16].author.id | https://openalex.org/A5086407321 |
| authorships[16].author.orcid | |
| authorships[16].author.display_name | Shreya Vemuri |
| authorships[16].countries | US |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I1334819555 |
| authorships[16].affiliations[0].raw_affiliation_string | Memorial Sloan-Kettering Cancer Center, New York, New York, United States |
| authorships[16].affiliations[1].institution_ids | https://openalex.org/I1334819555 |
| authorships[16].affiliations[1].raw_affiliation_string | Memorial Sloan-Kettering Cancer Center, New York, New York, United States. |
| authorships[16].institutions[0].id | https://openalex.org/I1334819555 |
| authorships[16].institutions[0].ror | https://ror.org/02yrq0923 |
| authorships[16].institutions[0].type | healthcare |
| authorships[16].institutions[0].lineage | https://openalex.org/I1334819555 |
| authorships[16].institutions[0].country_code | US |
| authorships[16].institutions[0].display_name | Memorial Sloan Kettering Cancer Center |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Shreya Vemuri |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Memorial Sloan-Kettering Cancer Center, New York, New York, United States, Memorial Sloan-Kettering Cancer Center, New York, New York, United States. |
| authorships[17].author.id | https://openalex.org/A5014543424 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-3001-4898 |
| authorships[17].author.display_name | Ariela Noy |
| authorships[17].countries | US |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I1334819555 |
| authorships[17].affiliations[0].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, New York, New York, United States |
| authorships[17].affiliations[1].institution_ids | https://openalex.org/I1334819555 |
| authorships[17].affiliations[1].raw_affiliation_string | Memorial Sloan Kettering Cancer Center, New York, New York, United States. |
| authorships[17].institutions[0].id | https://openalex.org/I1334819555 |
| authorships[17].institutions[0].ror | https://ror.org/02yrq0923 |
| authorships[17].institutions[0].type | healthcare |
| authorships[17].institutions[0].lineage | https://openalex.org/I1334819555 |
| authorships[17].institutions[0].country_code | US |
| authorships[17].institutions[0].display_name | Memorial Sloan Kettering Cancer Center |
| authorships[17].author_position | last |
| authorships[17].raw_author_name | Ariela Noy |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1182/bloodadvances.2025016168 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10185 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9990000128746033 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2734 |
| primary_topic.subfield.display_name | Pathology and Forensic Medicine |
| primary_topic.display_name | Lymphoma Diagnosis and Treatment |
| related_works | https://openalex.org/W2261314500, https://openalex.org/W2041230744, https://openalex.org/W2189404152, https://openalex.org/W2433456738, https://openalex.org/W4388066307, https://openalex.org/W2416632281, https://openalex.org/W616460830, https://openalex.org/W2014174060, https://openalex.org/W2152645133, https://openalex.org/W3029213536 |
| cited_by_count | 0 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1182/bloodadvances.2025016168 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764683450 |
| best_oa_location.source.issn | 2473-9529, 2473-9537 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2473-9529 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Blood Advances |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Blood Advances |
| best_oa_location.landing_page_url | https://doi.org/10.1182/bloodadvances.2025016168 |
| primary_location.id | doi:10.1182/bloodadvances.2025016168 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2764683450 |
| primary_location.source.issn | 2473-9529, 2473-9537 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2473-9529 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Blood Advances |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Blood Advances |
| primary_location.landing_page_url | https://doi.org/10.1182/bloodadvances.2025016168 |
| publication_date | 2025-07-17 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W3082090625, https://openalex.org/W2601989943, https://openalex.org/W2987417236, https://openalex.org/W3211879125, https://openalex.org/W2625330982, https://openalex.org/W2060527830, https://openalex.org/W2082140485, https://openalex.org/W1595368274, https://openalex.org/W2078256076, https://openalex.org/W4291111788, https://openalex.org/W2006070956, https://openalex.org/W4376225400, https://openalex.org/W2059409197, https://openalex.org/W2067337288, https://openalex.org/W2089756467, https://openalex.org/W2013744880, https://openalex.org/W3215289703, https://openalex.org/W2029409133, https://openalex.org/W4401209010, https://openalex.org/W2136216249, https://openalex.org/W3201026130, https://openalex.org/W4407395690 |
| referenced_works_count | 22 |
| abstract_inverted_index.1 | 152, 170 |
| abstract_inverted_index.2 | 63, 85, 107, 122, 158 |
| abstract_inverted_index.3 | 185, 189 |
| abstract_inverted_index.5 | 79, 91 |
| abstract_inverted_index.8 | 167 |
| abstract_inverted_index.9 | 113 |
| abstract_inverted_index.a | 27, 61, 124, 130 |
| abstract_inverted_index.13 | 118 |
| abstract_inverted_index.14 | 82 |
| abstract_inverted_index.17 | 179 |
| abstract_inverted_index.21 | 94 |
| abstract_inverted_index.CR | 131 |
| abstract_inverted_index.No | 101 |
| abstract_inverted_index.We | 59 |
| abstract_inverted_index.as | 13, 46, 261 |
| abstract_inverted_index.at | 173, 191, 259 |
| abstract_inverted_index.be | 232 |
| abstract_inverted_index.by | 88 |
| abstract_inverted_index.in | 71, 105, 129, 169, 251 |
| abstract_inverted_index.of | 53, 69, 134, 176, 207, 213, 223, 238, 245 |
| abstract_inverted_index.on | 41 |
| abstract_inverted_index.or | 5, 99 |
| abstract_inverted_index.to | 65, 195, 234 |
| abstract_inverted_index.CR, | 162 |
| abstract_inverted_index.CRR | 227 |
| abstract_inverted_index.MYC | 35 |
| abstract_inverted_index.R/R | 214, 253 |
| abstract_inverted_index.The | 33, 143 |
| abstract_inverted_index.and | 20, 56, 74, 112, 171, 205, 225, 247 |
| abstract_inverted_index.few | 31 |
| abstract_inverted_index.for | 78, 84, 90, 147 |
| abstract_inverted_index.had | 123, 187 |
| abstract_inverted_index.low | 226 |
| abstract_inverted_index.the | 67, 106, 117, 137, 157, 163, 174, 196, 210, 220, 236, 252 |
| abstract_inverted_index.was | 151, 166, 257 |
| abstract_inverted_index.15%, | 135 |
| abstract_inverted_index.This | 255 |
| abstract_inverted_index.acid | 43 |
| abstract_inverted_index.care | 224 |
| abstract_inverted_index.data | 177 |
| abstract_inverted_index.days | 80, 83, 92, 95 |
| abstract_inverted_index.have | 26 |
| abstract_inverted_index.line | 244 |
| abstract_inverted_index.made | 233 |
| abstract_inverted_index.rate | 132 |
| abstract_inverted_index.seen | 104 |
| abstract_inverted_index.such | 12 |
| abstract_inverted_index.time | 146, 175 |
| abstract_inverted_index.were | 103 |
| abstract_inverted_index.with | 2, 30, 39, 110, 114, 120, 149, 160, 219, 228, 241 |
| abstract_inverted_index.(BL), | 16 |
| abstract_inverted_index.(CR), | 127 |
| abstract_inverted_index.(CRR) | 133 |
| abstract_inverted_index.(R/R) | 7 |
| abstract_inverted_index.Among | 116, 156 |
| abstract_inverted_index.after | 181 |
| abstract_inverted_index.chest | 203 |
| abstract_inverted_index.cycle | 44 |
| abstract_inverted_index.daily | 77 |
| abstract_inverted_index.drug: | 198 |
| abstract_inverted_index.every | 81, 93 |
| abstract_inverted_index.first | 243 |
| abstract_inverted_index.grade | 188 |
| abstract_inverted_index.least | 192 |
| abstract_inverted_index.month | 153 |
| abstract_inverted_index.novel | 249 |
| abstract_inverted_index.pain, | 204 |
| abstract_inverted_index.phase | 62 |
| abstract_inverted_index.rapid | 140 |
| abstract_inverted_index.study | 182, 197 |
| abstract_inverted_index.their | 242 |
| abstract_inverted_index.these | 239 |
| abstract_inverted_index.trial | 64, 256 |
| abstract_inverted_index.until | 96 |
| abstract_inverted_index.(PBL), | 19 |
| abstract_inverted_index.(THL), | 25 |
| abstract_inverted_index.0-47). | 155 |
| abstract_inverted_index.B-cell | 10, 217 |
| abstract_inverted_index.R/R-BL | 150, 161 |
| abstract_inverted_index.dismal | 28, 211 |
| abstract_inverted_index.drives | 37 |
| abstract_inverted_index.entry. | 183 |
| abstract_inverted_index.events | 190 |
| abstract_inverted_index.median | 144 |
| abstract_inverted_index.months | 168, 180 |
| abstract_inverted_index.others | 138 |
| abstract_inverted_index.should | 231 |
| abstract_inverted_index.(range, | 154 |
| abstract_inverted_index.Burkitt | 14 |
| abstract_inverted_index.R/R-BL, | 72, 121 |
| abstract_inverted_index.R/R-PBL | 111 |
| abstract_inverted_index.current | 221 |
| abstract_inverted_index.cutoff, | 178 |
| abstract_inverted_index.cycles, | 86 |
| abstract_inverted_index.disease | 141 |
| abstract_inverted_index.efforts | 230 |
| abstract_inverted_index.explore | 66, 248 |
| abstract_inverted_index.improve | 235 |
| abstract_inverted_index.ongoing | 172 |
| abstract_inverted_index.outcome | 237 |
| abstract_inverted_index.primary | 3 |
| abstract_inverted_index.protein | 36 |
| abstract_inverted_index.related | 194 |
| abstract_inverted_index.therapy | 246 |
| abstract_inverted_index.whereas | 136 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Overall, | 184 |
| abstract_inverted_index.Patients | 1 |
| abstract_inverted_index.R/R-DHL, | 75 |
| abstract_inverted_index.R/R-PBL, | 73 |
| abstract_inverted_index.complete | 125 |
| abstract_inverted_index.disrupts | 50 |
| abstract_inverted_index.duration | 165 |
| abstract_inverted_index.efficacy | 68 |
| abstract_inverted_index.enrolled | 108 |
| abstract_inverted_index.followed | 87 |
| abstract_inverted_index.increase | 206 |
| abstract_inverted_index.lymphoma | 15, 18, 22, 24 |
| abstract_inverted_index.patients | 109, 119, 148, 159, 186 |
| abstract_inverted_index.possibly | 193 |
| abstract_inverted_index.relapsed | 6 |
| abstract_inverted_index.response | 126, 164 |
| abstract_inverted_index.setting. | 254 |
| abstract_inverted_index.standard | 222 |
| abstract_inverted_index.adenosine | 54 |
| abstract_inverted_index.conducted | 60 |
| abstract_inverted_index.follow-up | 145 |
| abstract_inverted_index.headache, | 201 |
| abstract_inverted_index.lymphomas | 218 |
| abstract_inverted_index.prognosis | 29, 212 |
| abstract_inverted_index.responses | 102 |
| abstract_inverted_index.resulting | 128 |
| abstract_inverted_index.therapies | 250 |
| abstract_inverted_index.toxicity, | 98 |
| abstract_inverted_index.troponin. | 208 |
| abstract_inverted_index.Devimistat | 49 |
| abstract_inverted_index.MYC-driven | 8, 215 |
| abstract_inverted_index.aggressive | 9, 216 |
| abstract_inverted_index.dependence | 40 |
| abstract_inverted_index.devimistat | 70 |
| abstract_inverted_index.double-hit | 21 |
| abstract_inverted_index.lymphomas, | 11 |
| abstract_inverted_index.noncardiac | 202 |
| abstract_inverted_index.production | 52 |
| abstract_inverted_index.refractory | 4 |
| abstract_inverted_index.registered | 258 |
| abstract_inverted_index.survivors. | 32 |
| abstract_inverted_index.Considering | 209 |
| abstract_inverted_index.deregulated | 34 |
| abstract_inverted_index.devimistat, | 229 |
| abstract_inverted_index.experienced | 139 |
| abstract_inverted_index.maintenance | 89 |
| abstract_inverted_index.precursors. | 48 |
| abstract_inverted_index.transplant. | 100 |
| abstract_inverted_index.R/R-DHL/THL. | 115 |
| abstract_inverted_index.administered | 76 |
| abstract_inverted_index.biosynthetic | 47, 57 |
| abstract_inverted_index.malignancies | 240 |
| abstract_inverted_index.neutropenia, | 199 |
| abstract_inverted_index.progression, | 97 |
| abstract_inverted_index.progression. | 142 |
| abstract_inverted_index.triphosphate | 55 |
| abstract_inverted_index.#NCT03793140. | 262 |
| abstract_inverted_index.intermediates | 45 |
| abstract_inverted_index.mitochondrial | 51 |
| abstract_inverted_index.plasmablastic | 17 |
| abstract_inverted_index.proliferation | 38 |
| abstract_inverted_index.tricarboxylic | 42 |
| abstract_inverted_index.intermediates. | 58 |
| abstract_inverted_index.(DHL)/triple-hit | 23 |
| abstract_inverted_index.thrombocytopenia, | 200 |
| abstract_inverted_index.www.ClinicalTrials.gov | 260 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 18 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.800000011920929 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.41729957 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |